美国食品药品监督管理局（FDA）已表态支持AEON Biopharma公司依照351(K)生物类似药审批路径所提出的分析相似性研究策略。这一积极信号意味着，AEON在推进其生物类似药研发过程中，所采用的关键技术路线获得了监管机构的认可。
美国食品药品监督管理局（FDA）已表态支持AEON Biopharma公司依照351(K)生物类似药审批路径所提出的分析相似性研究策略。这一积极信号意味着，AEON在推进其生物类似药研发过程中，所采用的关键技术路线获得了监管机构的认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.